Letrozole Zydus (Letrozole)

Letrozole blocks the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By inhibiting this conversion, circulating estrogen concentrations fall, depriving hormone‑sensitive breast cancer cells of the estrogen signal needed for proliferation.

The specific dose of Letrozole Zydus is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and individual factors. Healthcare professionals follow approved dosing guidelines and adjust as needed for safety and efficacy.

Letrozole is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant. Effective contraception is required during treatment.

To request Letrozole Zydus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor with a high potency and longer half‑life compared with earlier agents such as anastrozole. Clinical studies show comparable or slightly improved disease‑free survival in certain settings, but choice of agent depends on individual patient factors, tolerability, and physician preference.

Letrozole Zydus tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original container, protect from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Letrozole Zydus is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious risks include severe liver injury, osteoporosis‑related fractures, deep vein thrombosis or pulmonary embolism, and rare allergic reactions such as anaphylaxis. Patients should report any signs of jaundice, unexplained bone pain, swelling in the legs, or breathing difficulties to their clinician promptly.

Letrozole Zydus should not be used by pregnant or breastfeeding women, premenopausal women, or individuals with known hypersensitivity to letrozole or any tablet excipients. Caution is also advised for patients with severe liver impairment or uncontrolled cardiovascular disease.